PET scan in the staging of non-small cell lung cancer

Lung Cancer

Volumn 42, Issue 2 SUPPL., 2003, Pages 27-37

  Vansteenkiste, Johan F ^a,b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Carcinoma, non small cell lung; FDG; Guidelines; Lung neoplasm's; Lymphatic metastasis; Mediastinoscopy; Neoplasm's, metastasis; Neoplasm's, staging; Predictive value of tests; Review; Sensitivity and specificity; Tomography, emission computed

Indexed keywords

BRAIN METASTASIS; CANCER STAGING; CONFERENCE PAPER; DATA ANALYSIS; HUMAN; IMAGING; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; LYMPH NODE; MEDIASTINOSCOPY; MEDICAL ASSESSMENT; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZATION;

EID: 0242468818     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(03)00302-7     Document Type: Conference Paper

References (56)

1. Warburg O., Posener K., Negelein E. The metabolism of the carcinoma cell. Warburg O. The metabolism of tumors. 1931;129-169 Richard R. Smith, Inc, New York.
2. Ido T., Wan C., Carella V., Fowler J., Wolf A., Reivich M., Kuhl D. Labeled 2-deoxy-D-glucose analogs: 18F-labeled 2-deoxy-2-fluoro-D-glucose, 2-deoxy-2-fluoro-D-mannose and 14C-2-deoxy-2-fluoro-D-glucose. J. Label. Compds. Radiopharm. 24:1978;174-183.
3. Vansteenkiste J.F., Stroobants S.G. The role of positron emission tomography with 18F-fluoro-2-deoxy-D-glucose in respiratory oncology. Eur. Respir. J. 17:2001;802-820.
4. Phelps M.E., Huang S.C., Hoffman E.J., Selin C., Sokoloff L., Kuhl D.E. Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18)2-fluoro-2-deoxy-D-glucose: validation of method. Ann. Neurol. 6:1979;371-388.
5. Mortelmans L., Vanhaecke J., Lesaffre E., et al. Evaluation of the effect of thrombolytic treatment on infarct size and left ventricular function by enzymatic, scintigraphic and angiographic methods. Am. Heart J. 6:1990;1231-1237.
6. Nolop K.B., Rhodes C.G., Brudin L.H., Beany R.P., Krausz T., Jones T., Hughes J.M. Glucose utilization in vivo by human pulmonary neoplasms. Cancer. 60:1987;2682-2689.
7. Wahl R., Hutchins G., Bushsboaum D., Liebert M., Grossman H., Fisher S. 18F-2-deoxy-2fluoro-D-glucose uptake into human tumor xenografts: feasibility studies for cancer imaging with positron emission tomography. Cancer. 67:1991;1544-1550.
8. Gupta N.C., Frank A.R., Dewan N.A., et al. Solitary pulmonary nodules: detection of malignancy with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology. 184:1992;441-444.
9. Wahl R.L., Quint L.E., Greenough R.L., Meyer C.R., White R.I., Orringer M.B. Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images: preliminary prospective evaluation. Radiology. 191:1994;371-377.
10. Dwamena B.A., Sonnad S.S., Angobaldo J.O., Wahl R.L. Metastases from non-small cell lung cancer: mediastinal staging in the 1990s. Meta-analytic comparison of PET and CT. Radiology. 213:1999;530-536.
11. Coleman R.E., Laymon C.M., Turkington T.G. FDG imaging of lung nodules: a phantom study comparing SPECT, camera-based PET, and dedicated PET. Radiology. 210:1999;823-828.
12. Shreve P.D., Steventon R.S., Deters E.C., Kison P.V., Gross M.D., Wahl R.L. Oncologic diagnosis with 2-[fluorine-18]fluoro-2-deoxy-D-glucose imaging: dual-head coincidence gamma camera versus positron emission tomographic scanner. Radiology. 207:1998;431-437.
13. Carretta A., Landoni C., Melloni G., et al. 18-FDG positron emission tomography in the evaluation of malignant pleural diseases - a pilot study. Eur. J. Cardiothorac. Surg. 17:2000;377-383.
14. Erasmus J.J., McAdams H.P., Rossi S.E., Goodman P.C., Coleman R.E., Patz E.F. FDG PET of pleural effusions in patients with non-small cell lung cancer. Am. J. Roentgenol. 175:2000;245-249.
15. Webb W.R., Gatsouris S., Zerhouni E.A., et al. CT and MR imaging in staging non-small cell bronchogenic carcinoma: report of the Radiology Diagnostic Oncology Group. Radiology. 178:1991;705-713.
16. Dillemans B., Deneffe G., Verschakelen J., Decramer M. Value of computed tomography and mediastinoscopy in preoperative evaluation of mediastinal nodes in non-small cell lung cancer. Eur. J. Cardiothorac. Surg. 8:1994;37-42.
17. Saunders C.A., Dussek J.E., O'Doherty M.J., Maisey M.N. Evaluation of fluorine-18-fluorodeoxyglucose whole body positron emission tomography imaging in the staging of lung cancer. Ann. Thorac. Surg. 67:1999;790-797.
18. Valk P.E., Pounds T.R., Hopkins D.M., et al. Staging non-small cell lung cancer by whole-body positron emission tomographic imaging. Ann. Thorac. Surg. 60:1995;1573-1581.
19. Vansteenkiste J.F., Stroobants S.G., De Leyn P.R., et al. Lymph node staging in non-small cell lung cancer with FDG-PET scan: a prospective study on 690 lymph node stations from 68 patients. J. Clin. Oncol. 16:1998;2142-2149.
20. Kernstine K.H., Stanford W., Mullan B.F., et al. PET, CT, and MRI with Combidex for mediastinal staging in non-small cell lung carcinoma. Ann. Thorac. Surg. 68:1999;1022-1028.
21. Vansteenkiste J.F., Stroobants S.G., Dupont P.J., et al. FDG-PET scan in potentially operable non-small cell lung cancer: do anatometabolic PET-CT fusion images improve the localisation of regional lymph node metastases? Eur. J. Nucl. Med. 25:1998;1495-1501.
22. Vansteenkiste J.F., Stroobants S.G., De Leyn P.R., et al. Mediastinal lymph node staging with FDG-PET scan in patients with potentially operable non-small cell lung cancer: A prospective analysis of 50 cases. Chest. 112:1997;1480-1486.
23. Bury T., Paulus P., Dowlati A., et al. Staging of the mediastinum: value of positron emission tomography imaging in non-small cell lung cancer. Eur. Respir. J. 9:1996;2560-2564.
24. Weng E., Tran L., Rege S., et al. Accuracy and clinical impact of mediastinal lymph node staging with FDG-PET imaging in potentially resectable lung cancer. Am. J. Clin. Oncol. 23:2000;47-52.
25. Berlangieri S.U., Scott A.M., Knight S.R., et al. F-18 fluorodeoxyglucose positron emission tomography in the non-invasive staging of non-small cell lung cancer. Eur. J. Cardiothorac. Surg. 16:(1):1999;S25-S30.
26. Steinert H.C., Hauser M., Allemann F., et al. Non-small cell lung cancer: nodal staging with FDG PET versus CT with correlative lymph node mapping and sampling. Radiology. 202:1997;441-446.
27. Scott W.J., Gobar L.S., Terry J.D., Dewan N.A., Sunderland J.J. Mediastinal lymph node staging of non-small-cell lung cancer: a prospective comparison of computed tomography and positron emission tomography. J. Thorac. Cardiovasc. Surg. 111:1996;642-648.
28. Sasaki M., Ichiya Y., Kuwabara Y., et al. The usefulness of FDG positron emission tomography for the detection of mediastinal lymph node metastases in patients with non-small cell lung cancer: a comparative study with X-ray computed tomography. Eur. J. Nucl. Med. 23:1996;741-747.
29. Patz E.F., Lowe V.J., Goodman P.C., Herndon J. Thoracic nodal staging with PET imaging with 18FDG in patients with bronchogenic carcinoma. Chest. 108:1995;1617-1621.
30. McLoud T.C., Bourgouin P.M., Greenberg R.W., et al. Bronchogenic carcinoma: analysis of staging in the mediastinum with CT by correlative lymph node mapping and sampling. Radiology. 182:1992;319-323.
31. Bury T., Dowlati A., Paulus P., et al. Evaluation of the solitary pulmonary nodule by positron emission tomography imaging. Eur. Respir. J. 9:1996;410-414.
32. Pantel K., Izbicki J., Passlick B., et al. Frequency and prognostic significance of isolated tumour cells in bone marrow of patients with non-small cell lung cancer without overt metastases. Lancet. 347:1996;649-653.
33. Quint L.E., Tummala S., Brisson L.J., et al. Distribution of distant metastases from newly diagnosed non-small cell lung cancer. Ann. Thorac. Surg. 62:1996;246-250.
34. Erasmus J.J., Patz E.F., McAdams H.P., et al. Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography. AJR. Am. J. Roentgenol. 168:1997;1357-1360.
35. Boland G.W., Goldberg M.A., Lee M.J., et al. Indeterminate adrenal mass in patients with cancer: evaluation at PET with 2-[F-18]-fluoro-2-deoxy-D- glucose. Radiology. 194:1995;131-134.
36. Maurea S., Mainolfi C., Bazzicalupo L., et al. Imaging of adrenal tumors using FDG PET: comparison of benign and malignant lesions. AJR. Am. J. Roentgenol. 173:1999;25-29.
37. Bury T., Barreto A., Daenen F., Barthelemy N., Ghaye B., Rigo P. Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer. Eur. J. Nucl. Med. 25:1998;1244-1247.
38. Schirrmeister H., Guhlmann A., Elsner K., et al. Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus 18F-PET. J. Nucl. Med. 40:1999;1623-1629.
39. Moon D.H., Maddahi J., Silverman D.H., Glaspy J.A., Phelps M.E., Hoh C.K. Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma. J. Nucl. Med. 39:1998;431-435.
40. Cook G.J., Houston S., Rubens R., Maisey M.N., Fogelman I. Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. J. Clin. Oncol. 16:1998;3375-3379.
41. Weder W., Schmid R.A., Bruchhaus H., Hillinger S., von Schulthess G.K., Steinert H.C. Detection of extrathoracic metastases by positron emission tomography in lung cancer. Ann. Thorac. Surg. 66:1998;886-892.
42. Marom E.M., McAdams H.P., Erasmus J.J., et al. Staging non-small cell lung cancer with whole-body PET. Radiology. 212:1999;803-809.
43. Hustinx R., Paulus P., Jacquet N., Jerusalem G., Bury T., Rigo P. Clinical evaluation of whole-body 18F-fluorodeoxyglucose positron emission tomography in the detection of liver metastases. Ann. Oncol. 9:1998;397-401.
44. Delbeke D., Martin W.H., Sandler M.P., Chapman W.C., Wright J.K., Pinson C.W. Evaluation of benign vs malignant hepatic lesions with positron emission tomography. Arch. Surg. 133:1998;510-515.
45. Mac Manus M.P., Hicks R.J., Matthews J.P., et al. High rate of detection of unsuspected distant metastases by PET in apparent stage III non-small cell lung cancer: implications for radical radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 50:2001;287-293.
46. Stroobants S., Dhoore I., Dooms C., et al. Additional value of whole-body FDG-PET in the detection of distant metastases in patients with potentially operable non-small cell lung cancer. Clin. Lung Cancer. 4:2003;242-247.
47. Bury T., Dowlati A., Paulus P., et al. Whole-body 18FDG positron emission tomography in the staging of non-small cell lung cancer. Eur. Respir. J. 10:1997;2529-2534.
48. Pieterman R.M., Van Putten J.W., Meuzelaar J.J., et al. Preoperative staging of non-small cell lung cancer with positron emission tomography. N. Engl. J. Med. 343:2000;254-261.
49. Lewis P., Griffin S., Marsden P., Gee T., Nunan T., Malsey M., Dussek J. Whole-body 18F-fluorodeoxyglucose positron emission tomography in preoperative evaluation of lung cancer. Lancet. 344:1994;1265-1266.
50. Hicks R.J., Kalff V., Mac Manus M.P., et al. 18F-FDG PET provides high-impact and powerful prognostic stratification in staging newly diagnosed non-small cell lung cancer. J. Nucl. Med. 42:2001;1596-1604.
51. Seltzer M.A., Yap C.S., Silverman D.H., et al. The impact of PET on the management of lung cancer: The referring physician's perspective. J. Nucl. Med. 43:2002;752-762.
52. Van Tinteren H., Hoekstra O.S., Smit E.F., et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small cell lung cancer: the PLUS multicentre randomised trial. Lancet. 359:2002;1388-1393.
53. Patterson G.A., Piazza D., Pearson F., et al. Significance of metastatic disease in subaortic lymph nodes. Ann. Thorac. Surg. 43:1987;155-159.
54. Vansteenkiste J.F., De Leyn P.R., Deneffe G.J., Stalpaert G., Nackaerts K.L., Lerut T.E., Demedts M.G. Survival and prognostic factors in resected N2 non-small cell lung cancer: a study of 140 cases. The Leuven Lung Cancer Group. Ann. Thorac. Surg. 63:1997;1441-1450.
55. Vansteenkiste J., De Leyn P., Deneffe G., Menten J., Lerut T., Demedts M. Present status of induction treatment for N2 non-small cell lung cancer: a review. Eur. J. Cardiothorac. Surg. 13:1998;1-12.
56. Gupta N.C., Tamim W.J., Graeber G.G., Bishop H.A., Hobbs G.R. Mediastinal lymph node sampling following positron emission tomography with fluorodeoxyglucose imaging in lung cancer staging. Chest. 120:2001;521-527.